For adults with active non-radiographic axial spondyloarthritis
The first and only treatment to offer both self-injection and IV infusion dosing options that target IL-17A.*
Want to learn more about taking COSENTYX?
*For adults.
Real results. Real relief.†
COSENTYX can help with overall symptoms of non-radiographic axial spondyloarthritis (nr-axSpA).
1 YEAR, 16 WEEKS, #1 PRESCRIBED:
Many people taking COSENTYX for nr-axSpA felt at least a 40% overall symptom improvement at 1 year.‡§ Many saw similar results in as little as 16 weeks.¶
Most people who took COSENTYX for non-radiographic axial spondyloarthritis (nr-axSpA) not only had less spinal pain and morning stiffness, they also saw improvement in their ability to move, and felt better overall after just 16 weeks.¶
COSENTYX is the #1 prescribed# biologic treatment of its kind.||
†All results shown from clinical trials using subcutaneous (under the skin) injection. The FDA approval of the intravenous (IV) administration (injected into a vein) of COSENTYX is based on data showing that the amount of the medication in your body after it is given directly through IV was within the range that would be seen when given as SC.
‡38% of people with nr-axSpA taking COSENTYX vs 19% taking placebo.
§At one year, patients and doctors were told which medication was being used, which may affect results.
¶41% of people with nr-axSpA taking COSENTYX vs 28% taking placebo
#Across all indications.
||Treatment for nr-axSpA that targets IL-17A, one of the multiple molecules in the body that may play a role in inflammation.
How does COSENTYX work?
COSENTYX treats nr-axSpA by specifically targeting and blocking IL-17A, one of the multiple molecules that is believed to play a role in causing inflammation. It’s the first and only treatment to offer both self-injection and IV infusion dosing options that target IL-17A.**
**As of January 2024.